Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
复制标题
DOI：
10.26355/eurrev_202003_20715
复制
发表时间：
2020-03-01
影响因子：
3.3
通讯作者：
Unfer, V
中科院分区：
文献类型：
--
作者：
Bizzarri, M.;Lagana, A. S.;Unfer, V
Sars-CoV-2 (COVID-19) 的爆发给全世界人民的健康带来了严峻挑战。该疾病的治疗主要是支持性的，急性呼吸窘迫综合征引起的呼吸衰竭是很大一部分受影响患者的主要原因。初步数据指出，IL-6 的急剧增加和随后的细胞因子释放综合征可能是致命性间质性肺炎的发生的原因。通过用单克隆抗体阻断 IL-6 的特异性受体来抑制 IL-6 已被认为是一种有希望的尝试。在这里，我们评估了肌醇（一种已用于治疗新生儿呼吸窘迫综合征的多元醇）在下调 Sars-CoV-2 感染后炎症反应方面的潜在效用。事实证明，肌醇可以在多种情况下降低 IL-6 水平并减轻炎症级联反应，同时没有任何明显的副作用。人们很容易推测肌醇可能有助于控制 Sars-CoV-2 感染最可怕的影响。
The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection.